// App-Quantinova.ai

: Improved biochemical control with modified-release hydrocortisone overturns the impaired fludrocortisone effect in salt-wasting CAH patients

Researchers

Presenter

  • Lea Tschaidse

Principal Investigators

  • Nicole Reisch

  • Wiebke Arlt

  • Aude Brac De La Perriere

  • Angelica Linden Hirschberg

  • Anders Juul

  • Ashwini Mallappa

  • Deborah P Merke

  • John DC Newell-Price

  • Colin Graham Perry

  • Alessandro Prete

  • Aled Rees

  • Monica Stikkelbroeck

  • Phillippe A Touraine

  • Helen Coope

  • John Porter

  • Richard John M Ross

  • Marcus Quinkler

Medical Centers

  • Klinikum der Universität München, Standort Großhadern, München, Germany

  • Endokrinologie, Nephrologie und weitere Sektionen - Medizinische Klinik und Poliklinik IV - Campus Innenstadt, München, Germany

  • University of Birmingham, Surrey, United Kingdom

  • Louis Pradel Hospital, Lyon, France

  • Karolinska Institutet, Sweden

  • Rigshospitalet, Copenhagen, Denmark

  • AstraZeneca, Gaithersberg, MD, United States,

  • NIH Clinical Center, Bethesda, MD, United States

  • University of Sheffield, Sheffield, United Kingdom

  • Queen Elizabeth University Hospital, Glasgow, United Kingdom

  • Cardiff University, Cardiff, United Kingdom

  • Radboud University, Nijmegen, Netherlands

  • University Hospitals Pitié Salpêtrière - Charles Foix, Rheumatology, Paris, France

  • Diurnal, United Kingdom

  • Endokrinologie in Charlottenburg, Berlin, Germany

Locations

  • Germany

  • United Kingdom

  • France

  • Sweden

  • Denmark

  • United States

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Plasma Renin Activity

Drug/Treatment

  • Fludrocortisone

  • Hydrocortisone

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Prednisolone

  • Androgen Tear

Outcome

  • N/A


Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A